EPELEUTON, A NOVEL SYNTHETIC SECOND GENERATION W-3 FATTY ACID, PROTECTS HUMANIZED SICKLE CELL MICE AGAINST HYPOXIA/REOXYGENATION ORGAN DAMAGE
May 13, 2022Epeleuton receives orphan-drug designation for Sickle Cell Disease from the FDA
July 19, 2022Data Showing Epeleuton As A Potential Treatment For Sickle Cell Disease Will Be Presented At The EHA 2022 Congress
Dublin, Ireland, 10 June 2022: Afimmune, a privately held, clinical stage biopharmaceutical company, today announced that results of its investigational drug Epeleuton will be presented at the European Hematology Association (EHA) 2022 Congress, June 10-12, in Vienna Austria.
The study in the established humanised sickle cell mouse model, is focused on life-threatening acute sickle cell related complication, the acute vaso-occlusive crisis (VOC).
The poster details can be found below:
Session: Sickle Cell Disease
Abstract number: P1483
Presenter: Prof Lucia De Franceschi, University of Verona, Verona, Italy.
The presentation discusses the novel dual therapeutic effects of Epeleuton on factors associated with sickle cell disease and vaso-occlusive risk.
“The data highlights that in humanized sickle cell mice exposed to hypoxia/reoxygenation, which mimics acute vaso-occlusive crisis, Epeleuton acts as a novel agent. Epeleuton targets red cells/hemolysis, inflammatory response and vascular dysfunction” commented lead investigator Professor Lucia de Franceschi, University of Verona.
“Epeleuton’s data presentation supports the potential of Epeleuton as a new therapeutic option for Sickle Cell Disease, to be evaluated in future clinical trials“ said Prof Carlo Brugnara, Professor of Pathology at Harvard Medical School and Director of the Hematology Lab at Boston Children’s Hospital.
About Epeleuton
Epeleuton is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a novel synthetic fatty acid drug molecule. Epeleuton is a Phase 2 ready oral treatment.
About Sickle Cell Disease
Sickle Cell Disease (SCD) is a lifelong rare inherited disorder that affects red blood cells. SCD affects more than 100,000 people in the United States, approximately 52,000 people in Europe, and millions of people throughout the world. It is a serious and lifelong condition, and people with SCD experience many health problems and complications. People with SCD produce unusually shaped red blood cells that don’t survive as long as healthy blood cells and can block blood vessels. Pain is the leading cause of hospitalization. The hallmarks of SCD are these acute pain crises called vaso-occlusions that are a result of insufficient oxygen reaching tissues and organs
About Afimmune
Afimmune, headquartered in Dublin, Ireland, is a clinical stage drug discovery and development company working on new medicines to improve the quality of life for people with rare and inflammatory diseases.
Contact:
Afimmune: [email protected]